10-Q: Sonendo Inc. Reports Q3 2024 Results, Navigates Financial Challenges and Strategic Shifts

Sonendo Inc. reported its Q3 2024 results, showing a decrease in revenue but improved gross margins, while also navigating significant financial challenges and strategic changes including a reverse stock split and delisting from the NYSE.

Summary

• Sonendo Inc. reported a net loss of $7.5 million for the three months ended September 30, 2024, compared to a net loss of $17.0 million for the same period in 2023.
• Revenue for the quarter was $8.0 million, slightly down from $8.2 million in the prior year.
• The company's gross margin improved significantly to 41% from 11% in the same quarter of the previous year.
• Operating expenses decreased substantially, with selling and marketing expenses down 48%, general and administrative expenses down 37%, and research and development expenses down 43%.
• For the nine months ended September 30, 2024, the net loss was $21.7 million, compared to $50.0 million in the same period of 2023.
• Revenue for the nine-month period was $23.4 million, a decrease from $25.6 million in the prior year.
• The company's gross margin for the nine-month period improved to 36% from 9% in the prior year.
• The company completed the sale of its software segment, TDO Software Inc., on March 1, 2024, for approximately $16 million, recognizing a gain of $5.7 million.
• As of September 30, 2024, Sonendo had $17.3 million in cash and short-term investments and $17.8 million in outstanding principal under its term loan facility.
• The company implemented a 1-for-200 reverse stock split on October 18, 2024, to regain compliance with OTCQX listing requirements.
• Sonendo is facing substantial doubt about its ability to continue as a going concern without additional financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments like improved gross margins and reduced operating expenses, the significant net losses, delisting from the NYSE, and substantial doubt about the company's ability to continue as a going concern create a negative sentiment overall. The need for additional financing also adds to the uncertainty.

Positives

• Gross margins have improved significantly, indicating better cost management.
• Operating expenses have been substantially reduced, reflecting cost-cutting measures.
• The sale of the software segment generated a gain of $5.7 million.
• The company has taken steps to address its listing compliance issues with a reverse stock split.
• The company has reduced its net loss compared to the previous year.

Negatives

• Revenue decreased slightly for the quarter and nine-month period compared to the previous year.
• The company has a significant accumulated deficit of $451.7 million.
• There is substantial doubt about the company's ability to continue as a going concern without additional financing.
• The company's stock was delisted from the NYSE and is now trading on the OTCQX.
• The company received a notice from the OTC that its market capitalization no longer meets the continued qualification standards.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• Failure to comply with OTCQX listing requirements could result in the stock being moved to the OTC Pink market, further reducing liquidity and market value.
• The company's market capitalization has fallen below $5 million, triggering a cure period to regain compliance.
• The company is subject to various claims and legal proceedings, which could have a material adverse effect on its business.
• The company's revenue is primarily dependent on the sales of its GentleWave System and related instruments, making it vulnerable to market acceptance and competition.

Future Outlook

The company expects operating expenses to continue to decrease in 2024 and 2025 due to cost-saving measures. They also plan to continue investing in sales, marketing, research and development, and regulatory affairs. The company will require additional financing to fund its operations and planned growth.

Management Comments

• Management believes that the company's current targeting strategy identifies a well-defined customer base that is accessible by its direct sales organization.
• Management intends to increase awareness of the GentleWave Procedure among dental practitioners and, in select markets, directly with patients.
• Management is undertaking continuous cost-saving programs, including implementation of lean manufacturing methods and working with suppliers to reduce material costs.

Industry Context

The medical technology industry is highly competitive and rapidly changing. Sonendo's focus on innovative solutions for root canal therapy positions it in a niche market, but it faces challenges from established players and alternative treatments. The company's ability to gain market acceptance and achieve profitability will be crucial for its long-term success.

Comparison to Industry Standards

• Sonendo's gross margin improvement to 41% in Q3 2024 is a positive sign, but it still needs to be compared to industry benchmarks for medical device companies, which can vary widely depending on the specific sector and product type.
• Companies like Align Technology (ALGN) in the dental space have gross margins in the 70% range, while others like Medtronic (MDT) have margins in the 60-70% range, indicating that Sonendo has room for improvement.
• The significant reduction in operating expenses is a necessary step for Sonendo, as many early-stage medical device companies struggle with high burn rates. However, it's important to ensure that these cuts do not hinder future growth and innovation.
• The delisting from the NYSE and the potential move to the OTC Pink market are significant setbacks, as they can negatively impact investor confidence and access to capital. Companies like Cassava Sciences (SAVA) have faced similar challenges, highlighting the importance of maintaining listing compliance.
• Sonendo's reliance on a single product line (GentleWave System) makes it more vulnerable to market shifts and competition. Diversification of product offerings is a common strategy for medical device companies to mitigate risk, as seen with companies like Johnson & Johnson (JNJ) and Abbott (ABT).

Legal Proceedings

• The company is subject to various claims and legal proceedings, including those related to compliance with California wage and hour laws and derivative matters.
• On October 1, 2024, the company filed a proof of claim with the Bankruptcy Court for a total of not less than $59,000,000 in damages related to alleged patent infringement by Biolase.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial challenges, delisting from the NYSE, and potential move to the OTC Pink market.
• Employees may be affected by ongoing cost-cutting measures and potential restructuring.
• Customers may be impacted by the company's ability to continue operations and provide ongoing support for its products.
• Creditors face increased risk due to the company's financial instability and need for additional financing.

Next Steps

• The company will continue to monitor its market capitalization and consider available options to resolve the noncompliance with the OTCQX market capitalization requirement.
• The company will continue to explore financing options, including a combination of debt, equity, and non-dilutive sources.
• The company will continue to implement cost-saving measures to reduce negative cash flow.
• The company will continue to focus on driving adoption and utilization of the GentleWave System.

Key Dates

Keywords

Sonendo, GentleWave System, medical technology, dental, root canal therapy, financial results, reverse stock split, OTCQX, delisting, term loan, discontinued operations, TDO Software, gross margin, operating expenses, net loss